PALB2 Polyclonal Antibody [AT126]
- Known as:
- PALB2 Polyclonal Antibody [AT126]
- Catalog number:
- a-0505-100
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Epigentek inc
- Gene target:
- PALB2 Polyclonal Antibody [AT126]
Related genes to: PALB2 Polyclonal Antibody [AT126]
- Gene:
- PALB2 NIH gene
- Name:
- partner and localizer of BRCA2
- Previous symbol:
- -
- Synonyms:
- FLJ21816, FANCN
- Chromosome:
- 16p12.2
- Locus Type:
- gene with protein product
- Date approved:
- 2007-01-15
- Date modifiied:
- 2019-04-23
Related products to: PALB2 Polyclonal Antibody [AT126]
Related articles to: PALB2 Polyclonal Antibody [AT126]
- The utility of whole-genome sequencing (WGS) for detecting childhood leukemia predisposition remains unclear. We perform a nationwide, prospective, population-based study of 181 children with acute leukemia to assess diagnostic yield and clinical utility of a uniformly applied three-pronged strategy, including systematic phenotyping, germline WGS-based 189-gene panel and tumor sequencing of positive cases. Trio-WGS is performed in 11 high-suspicion families. Nine patients have pathogenic germline alterations: six (3.3%) with leukemia predisposition syndromes (TP53, CEBPA, DNMT3A, trisomy 21) and three (1.6%) with solid tumor predisposition syndromes (MSH6, PALB2, SDHA). Trio-WGS identifies one likely-pathogenic de novo DNMT3A variant. Six of nine diagnoses are previously unrecognized. Findings lead to tailored surveillance in 8/9 patients and treatment modifications in 4/9. Here, we show that this strategy gives a modest diagnostic yield. Nevertheless, the actionability of the findings supports its feasibility and validity in practice. Whether to restrict analysis to leukemia-relevant genes or broaden the panel should reflect local resources and counseling capacity. - Source: PubMed
Publication date: 2026/09/28
Taylan FulyaStaffas AnnaSjögren SaraLagerstedt-Robinson KristinaKuchinskaya EkaterinaPoluha AnnaIvarsson SofieHellberg MariaKlar JoakimAbel FridaAbrahamsson JonasPronk Cornelis JanBelander Strålin KarinHarila ArjaVogt HartmutNorén-Nyström UlrikaGrillner PernillaPalmqvist LarsArvidsson LindaPandzic TatjanaBondeson Marie-LouiseMu NinniEkholm KatjaAnderlid Britt-MarieGolovleva IrinaMaya-González CarolinaGideonsson PärTham EmmaBarbany GiselaLähteenmäki PäiviSandgren JohannaRosenquist RichardWirta ValtteriLjungman GustafGisselsson DavidPalle JosefineTesi BiancaNordgren Ann - Integrated tumour and germline testing is recommended for all patients with metastatic prostate cancer (mPCa), yet real-world implementation varies widely. Use of tumour analysis to stratify patients for germline testing (tumour-first workflow (TFW)) has emerged as an efficient triage strategy, but its performance relative to family history (FH)-based referral remains insufficiently characterised. - Source: PubMed
Publication date: 2026/09/19
Kloots Iris S HKets C MarleenSchuurs-Hoeijmakers JannekeKroeze Leonie IPillay Stephanievan Oort Inge MBloemendal Haiko JGerritsen Winald RLigtenberg Marjolijn J LMehra Niven - Standard hereditary breast cancer gene panels fail to identify causative variants in some patients meeting hereditary breast and ovarian cancer (HBOC) criteria. This exploratory, hypothesis-generating study characterised germline variants in , functionally related DNA damage response genes, and selected low-evidence candidate genes in breast cancer patients with uninformative standard panel results. A total of 185 patients meeting NCCN/ACMG criteria, with normal 42-gene panel and / MLPA results, underwent second-tier targeted sequencing. Group 1 comprised and related genes (, , , , ); Group 2 consisted of Genomics England PanelApp candidates (, , , , , ). No ethnically matched control cohort was available. Variants were classified per ACMG 2015 guidelines and confirmed by Sanger sequencing. Rare variants meeting reporting criteria were identified in 20/185 patients (10.8%): one likely pathogenic (LP) frameshift deletion (c.1869_1870del) in a luminal B invasive ductal carcinoma patient, nineteen variants of uncertain significance (VUS), and one unconfirmed copy number variant. was the most frequently implicated Group 2 gene (4 patients), including a homozygous variant; variants were identified in three patients, including the only male breast cancer case. These descriptive findings identify , , , , and as candidates warranting evaluation in case-control studies with ancestry-matched cohorts, functional validation, and family segregation analysis before any consideration for panel inclusion. - Source: PubMed
Publication date: 2026/09/14
Koç AltuğAtasoy VeyselÖzer Kaya ÖzgeKeşan SelcanSaka MerveAkcan Mehmet BerkayÖzdemir Taha ReşidErdoğan Kadri MuratBoz ÖzlemÖzyılmaz BerkÜnal Olçun ÜmitÇakıroğlu UmutAkay SevalEsenkaya Mehmet Erdinç - Although and remain the backbone for germline DNA testing of patients with breast cancer (BC) or ovarian cancer (OC), there are a number of other genes with proven or potential clinical significance. is associated with an elevated risk of BC, whereas pathogenic variants (PVs) in , , and are mainly relevant to OC development. Some germline findings are helpful in guiding therapeutic decisions: for example, , , and germline PVs render tumors sensitive to PARP inhibitors (PARPi), whereas cancers arising in heterozygotes are likely to be responsive to AKT down-regulators. , , , and PVs result in only a two-fold or even lower excess of cancer risk. However, the incorporation of these genes in DNA testing panels may occasionally lead to the identification of individuals with biallelic germline inactivation; these patients have a severe disease phenotype and thus require intensive medical intervention. The accumulation of data on "non-" BC- and OC-predisposing genes is complicated due to the rarity of their alterations, significant interethnic variations in population frequency of relevant PVs, heterogeneity of disease subtypes, etc. The use of extended gene panels, which pool together both clinically validated cancer-associated genes and "candidate" genes with potential but unproven significance, is likely to be a prevailing diagnostic approach in the next few years; therefore, proper attitudes towards accumulation and interpretation of genetic data are important. - Source: PubMed
Publication date: 2026/09/14
Imyanitov EvgenySokolenko Anna - Pancreatic cystic lesions are common during surveillance of individuals at hereditary risk for pancreatic cancer, but whether their incidence and progression differ across genetic risk groups remains uncertain. - Source: PubMed
Publication date: 2026/09/01
Dall'Olio TommasoCapurso GabrieleTerrin MariaDe Luca RaffaeleColuccio ChiaraArcangeli ValentinaMilanetto Anna CaterinaButturini GiovanniFantin AlbertoBarresi LucaDe Marchi GiuliaGalli AndreaDi Marco MarcoPanzuto FrancescoSassatelli RomanoRicci ClaudioDi Matteo Francesco MariaSpinelli ElideDal Buono AriannaPatruno MargheritaCavestro Giulia MartinaVenturini ElisaArcidiacono Paolo GiorgioSalvia RobertoFalconi MassimoCarrara SilviaArchibugi LiviaPaiella Salvatore